参考文献/References:
[1] 徐小元,丁惠国,李文刚,等.肝硬化诊治指南[J].临床肝胆病杂志,2019,35(11):2408-2425.
[2] 段钟平,令狐恩强,庄辉,等.肝硬化腹水及相关并发症的诊疗指南[J].实用肝脏病杂志,2018,21(1):21-31.
[3] GUARNER C,SORIANO G.Bacterial translocation and its consequences in patients with cirrhosis[J].Eur J Gastroenterol Hepatol,2005,17(1):27-31 .
[4] ACHARYA C,BAJAJ J S.Gut microbiota and complications of liver disease[J].Gastroenterol Clin North Am,2017,46(1):155-169.
[5] SANTIAGO A,POZUELO M,POCA M,et al.Alteration of the serum microbiome composition in cirrhotic patients with ascites[J].Sci Rep,2016,6:2500.
[6] KALAMBOKIS G N,MOUZAKI A,RODI M,et al.Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites[J].Clin Gastroenterol Hepatol,2012,10(7):815-818.
[7] 王贵强,王福生,庄辉,等.慢性乙型肝炎防治指南(2019年版)[J].肝脏,2019,24(12):1335-1356.
[8] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南[J].实用肝脏病杂志,2018,21(1):21-31.
[9] PIMENTEL M,SAAD R J,LONG M D,et al.ACG clinical guideline:small intestinal bacterial overgrowth[J].Am J Gastroenterol,2020,115(2):165-178.
[10] PLANAS R,MONTOLIU S,BALLEST B,et al.Natural history of patients hospitalized for management of cirrhotic ascites[J].Clin Gastroenterol Hepatol,2006,4(11):1385-1394.
[11] KANG S H,LEE Y B,LEE J H,et al.Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy[J].Aliment Pharmacol Ther,2017,46(9):845-855.
[12] GMEZ-HURTADO I,SANTACRUZ A,PEIR G,et al.Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis[J].PLoS One,2011,6(7):e23037.
[13] CALANNI F,RENZULLI C,BARBANTI M,et al.Rifaximin:beyond the traditional antibiotic activity[J].J Antibiot (Tokyo),2014,67(9):667-670.
[14] PONZIANI F R,ZOCCO M A,D′AVERSA F,et al.Eubiotic properties of rifaximin:disruption of the traditional concepts in gut microbiota modulation[J].World J Gastroenterol,2017,23(25):4491-4499.
[15] LAURTIANO E C,GABRIELLI M,SCARPELLINI E,et al.Antibiotic therapy in small intestinal bacterial overgrowth:rifaximin versus metronidazole[J].Eur Rev Med Pharmacol Sci,2009,13(2):111-116.
[16] MEYRAT P,SAFRONEEVA E,SCHOEPFER A M.Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months[J].Aliment Pharmacol Ther,2012,36(11/12):1084-1093.
[17] GATTA L,SCARPIGNATO C.Systematic review with meta-analysis:rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth[J].Aliment Pharmacol Ther,2017,45(5):604-616.
[18] PONZIANI F R,GERARDI V,PECERE S,et al.Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications[J].World J Gastroenterol,2015,21(43):12322-12333.
[19] LV X Y,DING H G,ZHENG J F,et al.Rifaximin improves survival in cirrhotic patients with refractory ascites:a real-world study[J].World J Gastroenterol,2020,26(2):199-218.
[20] HANAFY A S,HASSANEEN A M.Rifaximin and midodrine improve" clinical outcome in refractory ascites including renal function,weight loss,and short-term survival[J].Eur J Gastroenterol Hepatol,2016,28(12):1455-1461.
相似文献/References:
[1]梁宝松,杨玉秀,朱继德,等.乙型肝炎患者血清HBV—DNA与e系统对照分析[J].新乡医学院学报,1996,13(03):265.
[2]李旭英,李桂香,李焕芝,等.乙型肝炎后肝硬化上消化道出血的护理[J].新乡医学院学报,1997,14(04):417.
[3]王宪波,乔汉臣 桑雁,乔立新.愈肝汤对慢性乙型肝炎患者脂质过氧化和肝纤维化的影响[J].新乡医学院学报,2000,17(04):242.
[4]何松叶,贾晓娜,宋蓓.重组人干扰素a一2b治疗乙型和丙型肝炎的临床观察与护理[J].新乡医学院学报,2001,18(04):302.
[5]焦栓林,许丽芝,申德林,等.拉米夫定治疗慢性乙型肝炎过程中的YMDD变异及其临床意义[J].新乡医学院学报,2002,19(06):465.
[6]焦栓林,许丽芝,申德林,等.拉米夫定治疗慢性乙型肝炎过程中的YMDD变异及其临床意义[J].新乡医学院学报,2002,19(06):465.
[7]张志珊,蒋燕成,陈婉花,等.一种新型国产乙型肝炎病毒核酸定量检测试剂的临床应用效能评价[J].新乡医学院学报,2020,37(7):641.[doi:10.7683/xxyxyxb.2020.07.010]
ZHANG Zhishan,JIANG Yancheng,CHEN Wanhua,et al.Clinical application efficiency of a new type domestic hepatitis B virus nucleic acid quantitative detection kit[J].Journal of Xinxiang Medical University,2020,37(9):641.[doi:10.7683/xxyxyxb.2020.07.010]
[8]赵巍峰,王园园,李 赢,等.安络化纤丸和恩替卡韦联合治疗对乙型肝炎肝硬化代偿期患者肝纤维化和炎性因子的影响[J].新乡医学院学报,2019,36(4):319.[doi:10.7683/xxyxyxb.2019.04.005]
ZHAO Wei-feng,WANG Yuan-yuan,LI Ying,et al.Effect of Anluo Huaxian Wan combined with entecavir on the liver fibrosis and inflammatory factors in patients with compensatory hepatitis B cirrhosis[J].Journal of Xinxiang Medical University,2019,36(9):319.[doi:10.7683/xxyxyxb.2019.04.005]